1.
Covid-19 vaccine immunogenicity in people living with HIV-1
by Nault, Lauriane
Vaccine, 2022, Vol.40 (26), p.3633-3637
2.
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
by Monin, Leticia
The lancet oncology, 2021, Vol.22 (6), p.765-778
3.
4.
Enhancement of Ag85B DNA vaccine immunogenicity against tuberculosis by dissolving microneedles in mice
by Yan, Qinying
Vaccine, 2018, Vol.36 (30), p.4471-4476
5.
Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis
by Choi, Angela
Nature medicine, 2021, Vol.27 (11), p.2025-2031
6.
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial
by Huh, Warner K
The Lancet (British edition), 2017, Vol.390 (10108), p.2143-2159
7.
A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine
by Chu, Laurence
Vaccine, 2021, Vol.39 (20), p.2791-2799
8.
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
by Denkert, Carsten
The lancet oncology, 2018, Vol.19 (1), p.40-50
9.
Immunogenicity to poliovirus type 2 following two doses of fractional intradermal inactivated poliovirus vaccine: A novel dose sparing immunization schedule
by Anand, Abhijeet
Vaccine, 2017, Vol.35 (22), p.2993-2998
10.
The use and abuse of a 4-fold increase in antibody response to assess immunogenicity in early stage vaccine clinical trials
by Saul, Allan
Vaccine, 2020, Vol.38 (5), p.951-953
11.
12.
ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice
by Alharbi, Naif Khalaf
Vaccine, 2017, Vol.35 (30), p.3780-3788
13.
14.
15.
Delivery methods to increase cellular uptake and immunogenicity of DNA vaccines
by Jorritsma, S.H.T
Vaccine, 2016, Vol.34 (46), p.5488-5494
16.
COVID-19 vaccine – Long term immune decline and breakthrough infections
by Khoury, Johad
Vaccine, 2021, Vol.39 (48), p.6984-6989
17.
Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis
by Flacco, Maria Elena
The Lancet infectious diseases, 2018, Vol.18 (4), p.461-472
18.
19.
The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18–59 years: A phase I randomized, double-blinded, controlled trial
by Pu, Jing
Vaccine, 2021, Vol.39 (20), p.2746-2754
20.
Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer
by Ligumsky, Hagai
The lancet oncology, 2022, Vol.23 (2), p.193-195
